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3D pharmacophore models are three-dimensional ensembles of chemically
defined interactions of a ligand in its bioactive conformation. They represent an
elegant way to decipher chemically encoded ligand information and have there-
fore become a valuable tool in drug design. In this review, we provide an overview
on the basic concept of this method and summarize key studies for applying 3D
pharmacophore models in virtual screening and mechanistic studies for protein
functionality. Moreover, we discuss recent developments in the field. The combi-
nation of 3D pharmacophore models with molecular dynamics simulations could
be a quantum leap forward since these approaches consider macromolecule–
ligand interactions as dynamic and therefore show a physiologically relevant
interaction pattern. Other trends include the efficient usage of 3D pharmacophore
information in machine learning and artificial intelligence applications or freely
accessible web servers for 3D pharmacophore modeling. The recent developments
show that 3D pharmacophore modeling is a vibrant field with various applications
in drug discovery and beyond.
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1 | INTRODUCTION
Macromolecular biological structures such as proteins or DNA bind small organic molecules triggering functional modula-
tion and biological response. The way in which ligands bind to their macromolecular targets is based on a small set of chem-
ical interactions (chemical features), such as hydrogen bonds, charges, or lipophilic contacts. 3D pharmacophores represent
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an intuitive and powerful description of these interaction patterns. The high degree of abstraction in 3D pharmacophores
enables the rationalization of binding modes for chemically diverse ligands and, subsequently, rapid and highly efficient vir-
tual screening of molecular databases. Although the concept of 3D pharmacophores was developed at the beginning of the
19th century, virtual screening experiments were not performed until the late 80s and early 90s, when the first software
packages for database searches were released.1 The chemical space for molecules with a molecular weight below 500 Da is
estimated to contain at least 1060 organic molecules.2 Additionally, current developments in machine learning algorithms
allow for in silico generation of billions of theoretically synthesizable molecules.3 3D pharmacophores present a unique
opportunity to harvest the enormous available chemical space for drug-like molecules.
In this review, we give a comprehensive overview of 3D pharmacophore models, their usage in drug design, and
current developments in the field. We introduce the basic concept and summarize the underlying methodology for
describing binding modes and for applying 3D pharmacophore models in virtual screening. We highlight the power of
3D pharmacophore models in drug discovery by showcasing key studies for virtual screening as well as studies that aim
at a mechanistic understanding of protein functions. Moreover, we present and discuss current developments such as
the integration of molecular dynamics, the combination with machine learning, and freely accessible web services.
2 | THE PRINCIPLES OF 3D PHARMACOPHORES
3D pharmacophores capture the nature and three-dimensional arrangement of chemical functionalities in ligands that
are relevant for molecular interactions with the macromolecular target. Chemical functionalities are thereby classified
into more general pharmacophore features, for example, hydrophobic areas, aromatic ring systems, hydrogen bond
acceptors, hydrogen bond donors, negatively ionizable groups, and positively ionizable groups.4 Less common interac-
tion types that contribute to the binding of ligands, such as metal coordination and halogen bonds, are either already
implemented in most software packages or require user definition.5–7 Besides chemical nature and spatial arrangement,
3D pharmacophores can capture feature directionality in the case of hydrogen bonds and aromatic interactions.8 Addi-
tionally, spatial tolerance and weight can be fine-tuned for each pharmacophore feature to adjust its size and impor-
tance in the 3D pharmacophore. In order to describe the preferable shape of molecules in the binding site,
pharmacophore features are often combined with exclusion volume constraints (also referred to as excluded volume
constraints). For instance, an exclusion volume constraint may consist of a set of spheres that represent the protein resi-
dues imposing a barrier for binding of potential ligands.
Several 3D pharmacophore modeling programs have been developed, of which several are free for academic users
(Table 1). Although the exact definition and implementation of pharmacophore features and their characteristics may differ
between different 3D pharmacophore modeling programs, the underlying concept of 3D pharmacophores remains the same.
2.1 | 3D pharmacophore elucidation
3D pharmacophore elucidation methods can be classified as feature-based, substructure pattern-based, or molecular
field-based, depending on how the pharmacophore features are derived. Feature-based methods derive pharmacophore
features by filtering for geometric descriptors that match the characteristics of molecular interactions. Pattern-based
methods, such as those implemented in PHASE, LigandScout, and Catalyst, detect substructures for chemical features
in molecules. For example, all hydroxyl groups are defined as hydrogen bond donors and acceptors. In contrast, molec-
ular field-based methods such as FLAP and Forge sample the molecular surface of either ligand or macromolecular tar-
get with different chemical probes and calculate interaction energy maps which can be translated into pharmacophore
features. An additional distinction between 3D pharmacophore generation methods is based on the type of employed
data. This could be a set of active ligands, structural data on the ligand in complex with its macromolecular target, or
structural data of the macromolecular target alone (Figure 1).
2.1.1 | Ligand-based 3D pharmacophores
Ligand-based 3D pharmacophores are used when no structural information on the macromolecular target is available.
They are composed of chemical features shared by a set of active compounds that are important for the interaction with
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the target (Figure 1). Shared pharmacophore features are usually derived from the 3D alignment of different conforma-
tions of active compounds. 3D structures of the conformers are aligned so that the same pharmacophoric features are
located in similar positions. If all the aligned molecules share a certain feature at a specific position, a pharmacophoric
feature is placed at this position.18 3D alignments are often preceded by prefiltering steps based on quick distance
checks, which substantially reduce computational time. For instance, the HipHop algorithm in Catalyst uses “pruned
exhaustive search” and gradually builds-up shared 3D pharmacophores from the two-feature pharmacophores found in
conformers of molecules.12 In order to identify a shared 3D pharmacophore at each step, a precomputed list of all the
interfeature distances in the molecule is first checked to see whether the specific feature combination is present. This
prefiltering step is followed by alignment by least-squares fit of the features. LigandScout identifies optimal alignment
by first checking best pairings between two sets of pharmacophore features based on interfeature distances, followed by
alignment using the Kabsch algorithm.19 In some software packages, such as HypoGen in Catalyst, the derived three-
dimensional arrangement of chemical features can be correlated with biological activities of known actives.14,20,21 This
step can help to determine the importance of each feature for small molecule bioactivity.
However, it is important to note that bioactive conformations of the molecules are usually not known. Therefore,
ligand-based 3D pharmacophore software considers a set of low energy conformations for each molecule. Although
commercial conformer generation algorithms are generally successful in reproducing bioactive conformations, the
ligand-based 3D pharmacophore generation procedure is not guaranteed to yield an alignment with the bioactive con-
formations.22 Another limitation of ligand-based 3D pharmacophores is the dependence on structurally similar mole-
cules, since structurally more diverse molecules may not share the same binding mode and hence, require separate
pharmacophore models. But even if different molecules share a common binding mode, a correct alignment becomes
more challenging to the ligand-based algorithms the more diverse the molecules are.8
TABLE 1 3D pharmacophore modeling software, their components, and availability of free academic licenses





FLAP9 Ligand, complex, apo Molecular field Yes No
Pharmer10 Ligand, complex Substructure pattern, feature Yes Yes (GPLv2)
LigandScout11 Ligand, complex, apo Substructure pattern, feature, molecular field Yes No
Catalyst12 Ligand, complex, apo Substructure pattern, feature, molecular field Yes No
MOE13 Ligand, complex, apo Substructure pattern, feature, molecular field Yes No
PHASE14 Ligand, complex, apo Substructure pattern, feature, molecular field Yes No
Pharao15 Ligand Substructure pattern Yes Yes (GPLv2)
UNITY16 Ligand, complex Substructure pattern, feature Yes No
Forge17 Ligand Molecular field Yes Free for PhD students
Note: Software name describes virtual screening component. Names of 3D pharmacophore generation components in respective software suite may vary. 3D
pharmacophores are commonly derived from an overlay of small molecules (ligand), from a ligand bound to its macromolecular target (complex) or from the
macromolecular target alone (apo). Pharmacophore features are identified by analyzing molecular fields describing the potential interaction energy toward
molecular probes (molecular field), by searching for substructure patterns able to perform the respective interaction (substructure pattern) or by filtering for
geometric descriptors fulfilling the criteria for molecular interactions (feature).
aThe software website was searched, or holder of rights was asked for academic license conditions.
FIGURE 1 3D pharmacophore
generation approaches based on the
available data. 3D pharmacophores
can be generated from either a set of
known ligands, atomistic models of
ligand-macromolecular target
complexes or the sole
macromolecular (apo) target
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2.1.2 | Structure-based 3D pharmacophores
Structure-based 3D pharmacophore elucidation can be performed on atomistic models of two types of structures. In
macromolecule–ligand complexes, a ligand is present in the binding site of the target molecule (Figure 1). Ligands in
complex with a macromolecular structure are primarily either co-crystallized or docked into the target site. If there is
no available structure of a macromolecule–ligand complex, or no known ligands at all for a binding site, programs can
derive 3D pharmacophore models from atomistic models of apo structures (Figure 1; Table 1). These apo structures are
atomistic models of macromolecules bound to no ligand.
Apo 3D pharmacophore elucidation techniques are especially useful in cases where there are no known ligands,
necessitating a de novo approach to pharmacophore feature placement within the cavity. However, apo 3D
pharmacophore generation methods can also be useful when applied to structures of macromolecule–ligand complexes.
In this instance, they can be used to generate a novel 3D pharmacophore for the same active site that is unbiased by the
existing ligand. This can be used to explore a novel region of chemical space for the same binding cavity. Accordingly,
one of the strengths of 3D pharmacophore-based virtual screening is the potential for scaffold hopping afforded by the
arrangement of abstract features not bound to any specific ligand structure.
Though they are the most common drug targets, proteins are not the only macromolecular structures analyzed in
3D pharmacophore development. Programs including LigandScout and Catalyst (Table 1) can generate 3D
pharmacophore models based on nucleic acids. For example, Spitzer et al. generated a 3D pharmacophore hypothesis
for minor groove binders based on a DNA–ligand complex.23
Feature-based methods can be employed on macromolecule–ligand complexes as well as on empty binding sites.
Feature-based programs analyze a target–ligand complex and employ a set of chemical and geometric rules to identify
and classify target–ligand interactions, which then comprise the pharmacophore features.19 In an example of a feature-
based method being applied to an apo structure, a strategy was developed by Schrödinger whereby fragments are
docked into an apo binding site using the Glide XP docking program.24,25 The most energetically favorable fragment
docking poses are selected to construct the 3D pharmacophore hypothesis using Phase (Table 1).14
Molecular field-based methods, such as FLAP (Table 1), employ molecular interaction fields (MIFs) to identify hot-
spots for pharmacophore feature placement.9 A prominent tool for generating MIFs is the GRID software, which is well
known for its role in the discovery of the antiviral drug zanamivir.26,27 In principle, an evenly spaced grid is placed over
a predefined binding cavity, and probes are placed to sample the binding site. These probes take the form of moieties
representing the interactions most likely to occur between the macromolecule and ligand functional groups. As a next
step, the energy between probe and target structure atom is calculated to define interaction sites. Thus, these probes
can identify sites of favorable interactions with the macromolecule. These interaction energies generate MIFs, which
are contoured by energy to generate maps that describe how the interaction energy between the target and a given
probe varies over the surface of the target. Molecular field-based programs take the points where the energy of a MIF
represents a local minimum, termed “hotspots,” and convert them into pharmacophore features according to the type
of probe that forms the most energetically favorable interaction at this point. Molecular field-based hotspot detection
can also be performed by employing noncommercial software such as AutoGrid within AutoDock which provides
access to energy grid maps for various atom types.28,29
Programs creating pharmacophore features for apo binding sites generate a surplus of possible features. These must
be reduced to a reasonable number for virtual screening; a balance between enough features to allow for specificity, but
not too many features, as this would be too restrictive and could lead to false negatives. Some programs include a fea-
ture reduction functionality, but other programs output an initial, unrefined 3D pharmacophore. The initial unrefined
3D pharmacophore composed of many features must then be reduced by the user. Feature selection can be based on
information about the binding site and binding site-lining atoms, and according to which features of the binding site
the user would like the ligands to exploit. Feature reduction must not only be performed manually; HS-Pharm30 is an
example of a program that uses machine learning to reduce the number of initial 3D pharmacophore features, as dis-
cussed in the advanced section later.
2.2 | Pharmacophore-based virtual screening
In pharmacophore-based virtual screening, 3D pharmacophores developed from either a set of active ligands, a target–
ligand complex or the apo target, are screened against virtual libraries of molecules. Molecules that satisfy the query
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pharmacophore requirements are retrieved from the libraries. The prioritization of compounds by virtual screening can
dramatically increase the hit rate compared to in vitro high-throughput screenings and hence reduce the number of
compounds for experimental testing (Figure 2).
To address conformational flexibility of the molecules, conformer libraries for the screened compounds are prepared
before the screening step. It is worth mentioning that conformation generation is handled differently by screening soft-
ware packages. Some software packages, such as LigandScout, Catalyst, or MOE perform virtual screening on a pre-
generated set of conformations for each library molecule, while other software packages, such as PHASE, allow on-the-
fly conformer generation during the screening step sacrificing virtual screening speed.19,31,32 For more information on
conformer generation for virtual screening, the reader is encouraged to read available publications on this
topic.8,22,32–36
In the screening step, pharmacophoric features in the query pharmacophore are compared to pharmacophoric fea-
tures present in the molecules of the screened library. Comparison methods can be divided into two distinct
approaches: fingerprint-based and 3D alignment-based. Fingerprint-based methods, such as FLAP, primarily extract
information about feature presence and/or interfeature geometries into fingerprint-like descriptors, which enables
time-efficient similarity (e.g., using the Tanimoto coefficient) comparison between the query pharmacophore and the
conformer library. Alignment-based methods including LigandScout, Catalyst, and PHASE perform 3D alignment of
the pharmacophore feature set. A match is reported if the pharmacophoric feature set of a distinct conformation of a
molecule can be aligned to the feature set of the query pharmacophore. 3D alignment is computationally expensive and
time consuming, especially in the context of large molecular library screening. In order to reduce computational time,
3D alignment is often preceded by a fast prefiltering step based on feature-types, feature-counts, or fast distance checks.
FIGURE 2 Virtual screening
workflow. 3D pharmacophores are
generated with either structure- or
ligand-based approaches. State-of-the
art retrospective validation is
performed by plotting ROC curves
with elaborated sets of actives and
decoys. Pharmacophore-based virtual
screening is often followed by
computationally more expensive
methods such as docking or
molecular dynamics simulations to
get more differentiated structural
insights. ROC, receiver operating
characteristics
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LigandScout is the only program that provides loss-less prefiltering steps, providing the most geometrically most accu-
rate screening algorithm. Additionally, its unique pattern-matching 3D alignment algorithm results in screening hit
lists that are orthogonal to other programs, mainly relying on interfeature distance fingerprints.37
In cases where experimental data for binding ligands is available, derived 3D pharmacophore models can be vali-
dated. Usually, a validation set for 3D pharmacophores contains reported active, inactive and decoy molecules. Two
points should be taken into consideration when preparing the validation set: Firstly, 3D pharmacophores describe a
unique binding pose. Therefore, the active set should include molecules that share the same binding mode within the
target protein. Secondly, reported inactives should be included with caution, as observed inactivity may result from
other factors, for example, insolubility or inability to reach the target in cell-based assays. Therefore, the use of carefully
selected decoys is encouraged over inactive molecules. A decoy is a compound presumed to be inactive and showing a
high similarity in physicochemical properties to the active compounds. The Directory of Useful Decoys (DUD-E) pro-
vides a convenient web-based tool for the generation of decoys.38 Subsequent screening against a validation set can be
used to assess the quality of the developed 3D pharmacophore, and to further optimize it (Figure 2).
When evaluating the quality of a 3D pharmacophore model by its performance in virtual screening, various metrics,
or enrichment parameters, are employed (Figure 2). 3D pharmacophore performance is evaluated in terms of how
many actives the 3D pharmacophore can retrieve from a data set, and how well the 3D pharmacophore is able to cor-
rectly classify compounds as active or inactive. Enrichment parameters classify the compounds in the data set into one
of four categories: active (true positive, TP); inactive but identified as active (false positive, FP); inactive (true negative,
TN); active but classed as inactive (false negative, FN). Different metrics measure different aspects of 3D
pharmacophore performance. These metrics include the yield of actives (YA), which describes the number of true posi-
tives present in the list of total hits retrieved by the 3D pharmacophore.39 Receiver operating characteristics (ROC) cur-
ves plot the rate of true positives identified over the rate of false positives, thus displaying the sensitivity and specificity
of the 3D pharmacophore model, characterizing how many active hits the 3D pharmacophore can identify in relation
to how many inactive compounds it misidentifies as active.39–41 For a comprehensive list of enrichment parameters,
how they are calculated, and their uses, the reader is referred to Braga and Andrade.40
After a 3D pharmacophore has been developed and retrospectively validated, it can be used to screen available com-
mercial or in-house compound libraries (Figure 2). Depending on the complexity of the 3D pharmacophore and the size
of the library, hit lists of various sizes will be retrieved by pharmacophore screening. 3D pharmacophore-based screen-
ing is often followed by further characterization of the binding mode with methods like molecular docking, targeted
molecular dynamics simulations, or other methods to gain more structural information to rationally prioritize mole-
cules for experimental testing (Figure 2).
3 | APPLICATION CASE STUDIES
3.1 | Virtual screening
Besides molecular docking, 3D pharmacophores are widely applied for virtual screening. In this section, we highlight
and discuss recent success stories of virtual screening campaigns covering different target classes and methodologies.
3.1.1 | Balancing the immune system with small molecule modulators
Toll-like receptors (TLRs) act as key players in the activation of the innate immune response by recognizing molecular
patterns associated with infections and nonphysiological tissue damage.42 Rational design of small molecule TLR mod-
ulators is a promising strategy to treat autoimmune inflammation, cancer, or allergies, or to identify adjuvants for
vaccines.43
In 2014, Murgueitio and colleagues were facing a sparse data scenario with no small organic TLR2 inhibitors avail-
able.44 Therefore, they generated a 3D pharmacophore based on MIFs to define key interactions necessary for ligand
binding. A structure-based pharmacophore model was carefully developed. Subsequent virtual screening revealed novel
antagonists in the low micromolar range with biological activity for 20% of their virtual hits. With more small organic
TLR2 ligands reported later on, Murgueitio and colleagues continued their efforts in searching for novel TLR2
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modulators and used a combined 3D pharmacophore and shape-based approach to discover a novel pyrogallol-based
compound (MMG-11) through virtual screening.45,46
In 2019, Šribar and co-workers conducted a structure-based virtual screening followed by in vitro experimental vali-
dation in seeking novel TLR8 modulators.47 Molecular docking was performed to explore different binding modes able
to explain the activity of known modulators. The most descriptive binding mode was translated into a 3D
pharmacophore that was subsequently employed for virtual screening. This approach finally led to a novel chemotype
for TLR8 inhibitors, where 36% of the molecules retrieved by this virtual screening approach showed activity in vitro.
3.1.2 | Discovery of novel covalent binding ligands
The design of covalent-binding ligands has gained increased popularity in the drug discovery community.48,49 Pro-
longed residence time on targets and pharmacodynamic effects independent from pharmacokinetics allow for lower
doses or longer dosage intervals, making covalently binding drugs attractive for many therapies.50,51 Covalent docking
and quantum mechanics (QM) calculations represent the “gold-standard” for the development of covalent binders.52,53
Docking is suitable for screening of small compound libraries, whereas QM calculations can be applied for single com-
pounds only, due to high computational costs and time. For virtual screening of large databases, a pharmacophore-
based approach is more applicable. Schulz and colleagues introduced a novel feature called “residue bonding point,”
which recognizes drug-like warheads, such as ketones, nitriles, or Michael acceptors, to the LigandScout
framework.11,54
They employed the residue bonding point feature, also referred to as “covalent feature,” for the de novo design of
viral 3C protease inhibitors.54 A selective and specific 3D pharmacophore was generated that included noncovalent
interactions crucial for substrate-recognition, as well as the novel covalent feature. The obtained 3D pharmacophore
was used for virtual screening of a fragment library. Compounds showing a high similarity of docking poses in covalent
and noncovalent form were selected for in vitro testing. Compound F1, a heterocyclic aromatic ketone, showed the
highest inhibitory activity in an enzymatic assay (Figure 3). The covalent binding to the Coxsackievirus (CV) B3 prote-
ase was proven with protein mass spectrometry. Compound F1 was optimized using a scaffold-hopping strategy, yield-
ing in the more stable and active hit C5, a phenylthiomethyl ketone. This compound was modified using synthetic
approaches to produce 7a, a selective and irreversible covalent inhibitor of CV B3 and Enterovirus (EV) D68 protease.
This example illustrates the ability of 3D pharmacophore models to not only identify novel ligands, but also their suit-
ability for hit and lead optimization. Additionally, this study highlights the applicability of 3D pharmacophores for
increasingly popular fragment-based drug discovery campaigns.55
3.1.3 | Targeting GPCRs with 3D pharmacophores
G protein-coupled receptors (GPCR) are important drug targets due to their omnipresence in human tissues, accessibil-
ity to drugs, and regulatory roles in many physiological and pathophysiological processes.56 Therefore, they are widely
targeted by virtual screening campaigns in search of novel bioactive ligands.
In 2017, Frandsen and colleagues used an in-house developed method to build a histamine H3 receptor (H3R)
pharmacophore model for virtual screening campaigns.57 Ligand-residue fragments were extracted from available
GPCR crystal structures and mapped to the same conserved binding pocket residues of the target receptor.58 This
method allows for structure-based modeling of orphan receptors with insufficient structural data or unknown ligands.
Due to its reliance on existing ligand-receptor fragments from only 62 GPCR crystal structures, the initial H3R
pharmacophore model missed an important cationic feature, which was added through docking studies and the
matching of known H3R ligands to the apo pharmacophore model. Pharmacophore features were placed with Phase.14
Virtual screening, hit selection, and generation of analogue from potent ligands amounted to 76 compounds being phar-
macologically tested with an IP1 accumulation and radioligand binding assay. Five neutral antagonists and one inverse
agonist showed binding in the low micromolar range, resulting in a hit rate of 8%.
Another approach was followed by Schaller and co-workers using a ligand-guided homology modeling strategy to
discover novel H3R ligands.59 A key aspect of this approach is the prioritization of a set of 1,000 homology models based
on their ability to explain the binding of nine known antagonists. The selected homology model was subsequently used
for 3D pharmacophore model generation with LigandScout.11 Complementarily, 10 diverse H3 receptor ligands were
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docked and evaluated by their interaction pattern. Resulting 3D pharmacophore models were iteratively optimized and
validated with a set of 100 diverse active compounds and 3,051 decoys, using the three best performing 3D
pharmacophore models for parallel virtual screening. Subsequently, eight hit molecules were selected for biological test-
ing of which two showed nanomolar affinities in a radioligand depletion assay, resulting in a hit rate of 25%.
3.1.4 | Design of multitarget ligands for controlling inflammation
The arachidonic acid (AA) cascade is a key biochemical pathway for the inflammatory response involving the produc-
tion of pro-inflammatory lipid mediators such as leukotrienes via 5-lipoxygenase-activating (FLA) protein, but also for
anti-inflammatory mediators like epoxyeicosatrienoic acids. The latter are hydrolyzed by soluble epoxide hydrolase
(sEH). The simultaneous inhibition of both enzymes therefore represents a promising approach for controlling inflam-
mation mediators derived from AA. Schuster and co-workers applied a pharmacophore-based virtual screening to dis-
cover the first dual inhibitor of FLA protein and sHE with activities in the nanomolar range.60 In a first step, they
virtually screened the SPECS library with two different ligand-based pharmacophore models both derived from known
FLA protein inhibitors. Twenty selected hit molecules were further prioritized by previously reported structure-based
sHE models and resulted in one novel and potent dual FLA protein/sHE inhibitor.61 Since multitarget approaches are
getting more and more attention, this example shows that ligand-based pharmacophores could have some benefits
when applying on multiple targets that bind chemically similar physiological ligands. Moreover, it highlights the poten-
tial of combining ligand and structure-based models in multitarget approaches, in which one 3D pharmacophore serves
as a prioritization tool for the hitlist derived by the other model.
3.1.5 | Design and optimization of novel agents in crop science
A successful application of ligand-based design in crop sciences was demonstrated by Yao et al. by targeting an enzyme
in plant-pathogenic fungi.62 The group performed pharmacophore-based virtual screening to find inhibitors of succi-
nate dehydrogenase (SDH). This protein is involved in the electron transport chain in eukaryotic mitochondria and rep-
resents a validated target for pesticides. All marketed SDH inhibitors consist of a carboxylate and amine-moiety
coupled to an aromatic amide. Yao et al. generated a ligand-based 3D pharmacophore containing aromatic, lipophilic,
and amide features applying Catalyst. The 3D pharmacophore was validated and used for a virtual screening campaign
of a focused amide library developed in-house. To construct the focused amide library, diverse commercially available
carboxylate moieties were linked to aniline using Discovery Studio's Enumerate Library by Reaction protocol to explore
FIGURE 3 Discovery of
covalent inhibitors of viral 3C
protease. The initial fragment was
identified with a 3D pharmacophore
and further optimized by scaffold
hopping and subsequent fragment
growing. Green arrow—hydrogen
bond donor, red arrow—hydrogen
bond acceptor, yellow sphere—
lipophilic contact, orange sphere—
residue binding point
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the chemical space of carboxylate-cores. After virtual screening of the focused library, 16 compounds were selected for
in vivo testing. Eight compounds showed more than 50% inhibition when tested against three different fungi species at
a concentration of 100 mg/L. The ligand showing the highest and broadest activity was optimized via synthesis. In a
second focused amide library, diverse amine moieties were linked to the best carboxylate core and screened against the
3D pharmacophore. The resulting collection of derivatives was tested in vitro on SDH. By combining in silico and
experimental optimization steps, a broadly active novel amidic SDH inhibitor with low micromolar activity was
developed.
3.2 | Understanding protein functionality
Besides describing ligand binding modes and virtual screening applications, 3D pharmacophores are powerful tools to
investigate ligand-dependent protein functionality on a mechanistic level. The following paragraphs showcase examples
where 3D pharmacophore models play an essential role in contributing to the mechanistic understanding of pharmaco-
logical effects.
3.2.1 | Modeling metabolism
Sulfotransferases (SULTs) play an important role in phase II metabolism, but represent challenging targets due to their
high flexibility and broad substrate specificity. Rakers and colleagues developed a pharmacophore-based SULT predic-
tion model to discriminate between substrates, inhibitors, and ligands that show both characteristics dependent on their
concentration.63 This study is remarkable for two reasons. Firstly, it uses an ensemble of different enzyme conforma-
tions derived from molecular dynamics (MD) simulations to generate conformation-specific 3D pharmacophore models.
Secondly, the pharmacophore fit score was incorporated into a machine learning approach based on support-vector
machines for post-filtering of screening results. The resulting pharmacophore-based prediction model was successfully
applied to the screening and classification of ligand types for SULT1E1 and enhances our understanding of SULT
enzyme specificity.
The aryl hydrocarbon receptor (AHR) is a ligand-dependent transcription factor controlling the metabolism of phys-
iological substances and xenobiotics. Based on carefully validated homology models, Tkachenko and colleagues applied
3D pharmacophore models to study differences between physiological ligands and xenobiotics with regard to AHR
transport to the nucleus and subsequent induction of CYP1A1.64 Histidine 291 was identified as a key residue, which
controls both functionalities, but with different roles in binding of physiological ligands such as kynurenine and xenobi-
otics such as β-naphtoflavone.
3.2.2 | Investigating ligand-dependent receptor function
GPCRs represent an important drug target class with highly complex pharmacology and various possibilities to modu-
late receptor function in a ligand-dependent manner. One major issue in this field is receptor selectivity, especially for
closely related subtypes of the same family. In order to understand subtype selectivity of bitopic (dualsteric) ligands at
muscarinic receptors, Bermudez and co-workers used 3D pharmacophore models to identify subtype-specific interac-
tion patterns.65 This rationally explained, on the one hand, how ligands achieve selectivity for a certain subtype, and,
on the other, identified key residues in the extracellular loop regions (e.g., a M3-specific salt bridge) that account for
subtype-specific receptor functionality. Some of the aforementioned bitopic ligands for the M2 receptor showed some
unexpected yet interesting pharmacological properties, such as partial agonism and pathway-specific receptor activation
(biased signaling). In order to understand these effects, 3D pharmacophore models were combined with other modeling
techniques and pharmacological experiments.66,67 The partial agonism could be explained by the existence of multiple
binding modes, which stabilize different activation states of the receptor. This concept was validated by experiments
and resulted in the rational design of a full agonist, which can only adopt the binding mode stabilizing active receptor
states.66 The pathway-specificity of the biased ligands was studied in a similar setting and resulted in a mechanistic
model whose key concept resides in the conformational restriction of the extracellular loop region.67–69 In another
study, the effect of fluorination of the photoswitchable azobenzene core was investigated in muscarinic agonists. This
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study shows that fluorination of the photoswitch alters not only the photochromic behavior but also the pharmacologi-
cal profile at the M1 receptor, due to additional interaction possibilities.70 In all of these GPCR studies, 3D
pharmacophores were key to understanding ligand-dependent receptor functions and, moreover, turned out to serve as
the optimal instrument for communication with synthetic chemists and pharmacologists.
4 | ADVANCED APPROACHES EMPLOYING 3D PHARMACOPHORE
PRINCIPLES
In the previous sections, we gave an overview of the concept of 3D pharmacophores and on which established software
is available. Additionally, we presented several state-of-the-art application case studies employing 3D pharmacophores
for prospective virtual screening and for understanding protein functionality. But what could be considered an
advanced approach? Typically, 3D pharmacophores are generated from atomistic models of macromolecules or from an
alignment of multiple ligand conformations and are employed for analysis of structure–activity relationships or virtual
screening campaigns. Moreover, a local installation of software and the availability of a high-performance computer are
usually mandatory to perform virtual screening experiments. In the following section, we introduce advanced
approaches that integrate conformations from MD simulations, employ machine learning algorithms, and provide
access to 3D pharmacophore searches without the requirement of expensive licenses and high-performance computers
(Table 2).
4.1 | Integration of information from molecular dynamics simulations
Since both macromolecules and ligands are dynamic entities, it becomes apparent that this also holds true for
macromolecule–ligand complexes and the underlying interactions. Following this idea, Carlson and colleagues inte-
grated information from MD simulations in the development of an enhanced 3D pharmacophore model to virtually
screen for novel HIV-1 integrase inhibitors.92 Later, Carlson used the HIV-1 protease to show that a 3D pharmacophore
generated from an ensemble of 28 NMR conformations performs better than a 3D pharmacophore generated from
90 X-ray structures.93 This pioneering work inspired other researchers and kick-started the development of several
methods employing conformations from MD simulations for 3D pharmacophore generation.
Hydration-site-restricted pharmacophore (2012). Unrefined 3D pharmacophore models generated from apo binding
cavities usually contain too many features for efficient virtual screening. The hydration-site-restricted pharmacophore
(HSRP) approach aims at reducing the number of pharmacophore features by identifying hydration sites on the protein
surface, whose water molecules suffer from unfavorable thermodynamic properties as calculated from MD simula-
tions.71 These restricted 3D pharmacophores also should be more likely to retrieve entropically favorable ligands. The
HSRP approach was evaluated for three pharmaceutically relevant target proteins, showing a successful reduction of
pharmacophore feature space with a simultaneous decrease in required computing power.
SILCS-Pharm (2014). SILCS-Pharm exploits binding hotspots of probe molecules in MD simulations for 3D
pharmacophore generation.72,73 The SILCS (site identification by ligand competitive saturation) method is employed to
sample the surface of proteins in MD simulations with different probe molecules reassembling properties known from
pharmacophore features, for example, benzene carbons for aromatic features.94 The resulting probability maps of the
different probe molecules (FragMaps) are Boltzmann-transformed into free energy representations. These free energy
FragMaps are finally converted to pharmacophore features and the associated free energies can be used to prioritize fea-
ture selection in 3D pharmacophore model generation. The authors showed that 3D pharmacophores generated with
SILCS-Pharm often perform better than various docking approaches and 3D pharmacophores generated with the HSRP
method described above. SILCS-Pharm was already employed in guiding binding pose predictions of novel inhibitors
targeting the oncoproteins Mcl-1 and Bcl-xL.95
Dynophores (dynamic pharmacophores) (2015). Contrary to approaches that gather pharmacophore information
from ensembles of different protein conformations based on MD, the dynophore app represents a fully automated
implementation of chemical feature-based interaction patterns with MD-based conformational sampling.66,74
Dynophores (dynamic pharmacophores) sequentially extract interaction points (such as hydrogen bonds, charges, or
lipophilic contacts) from each frame of a trajectory according to the ligand atoms involved and their feature type. The
resulting super-features can be statistically characterized by occurrence frequency and interaction patterns with the
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protein. Three-dimensional volumetric feature density clouds provide information about the spatial distribution of
interactions and barcode plots show the feature occurrence in a time-resolved manner. The dynophore app was
implemented within the ilib/LigandScout framework11 and addresses two shortcomings of classical 3D pharmacophore
models: their static character and the geometric simplification of the features.
The application of dynophores proved essential in several studies for rationally explaining phenomena which could
not have been unveiled by classical 3D pharmacophores alone. Dynophores were first used to explain an activity cliff of
two ligands at the M2 receptor, which differ in structure by a single double bond (dihydroisoxazole vs. isoxazole moiety)
and therefore show the same static 3D pharmacophore.66 Based on the occurrence frequency and the respective geo-
metric properties of a hydrogen bond acceptor, different strengths of the resulting hydrogen bond between the two
ligands could be rationalized. In another example, dynophores were able to unveil a mechanism to overcome drug resis-
tance for HIV-1 reverse transcriptase (RT). In this study, the RT inhibitor rilpivirine was shown to bypass resistance
mutations by interacting with alternate residues, stabilizing the inhibitor in the binding pocket.96 In a virtual screening
campaign against the metalloenzyme arginase, dynophores were employed to explore the plasticity of the binding
pocket in the presence of small molecule inhibitors and suggested the possibility for additional lipophilic contacts. This
resulted in two novel fragment arginase inhibitors that could aid the development of anticancer drugs.97 The dynophore
methodology enables researchers to escape the static nature of classical 3D pharmacophore approaches and provides
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new opportunities to describe and analyze ligand binding modes as dynamic events (Figure 4).47,66,96–101 The probability
density functions representing the feature distribution of the super-features can be directly used for virtual screening,
providing new possibilities for efficiently incorporating information from molecular dynamics simulations into fast and
efficient virtual screening.
Common hits approach and MYSHAPE (2017). These two approaches select and optimize 3D pharmacophores based
on MD simulations. The Common Hits Approach (CHA) groups 3D pharmacophore models obtained from protein–
ligand conformations of MD simulations according to their interaction pattern.75 Representative 3D pharmacophores
are subsequently used for computationally costly virtual screening. CHA was retrospectively evaluated on 40 protein–
ligand systems, showing improved virtual screening performance for many of the protein–ligand complexes compared
to the use of single 3D pharmacophore models. In contrast, MYSHAPE optimizes shared-feature pharmacophores by
focusing on pharmacophore features observed during MD simulations of different protein–ligand complexes. This
approach was found in a retrospective evaluation against PPARɑ to perform better than 3D pharmacophores derived
from X-ray structure.76
GRAIL (2018). The GRids of phArmacophore Interaction fieLds (GRAIL) approach depicts MIFs on the
pharmacophore level in MD simulations.77 Beside pharmacophoric interaction fields, this approach generates informa-
tion on atom densities for protein, water, and ligand if present. GRAIL was applied to MD simulations of heat shock
protein 90 showing that the pharmacophoric interaction fields can contribute to the understanding of the structure–
activity relationship of a complexed ligand series.
Water pharmacophore (2018). The Water Pharmacophore (WP) method aims at generating 3D pharmacophores
based on thermodynamic properties of hydration sites, similar to the HSPR approach described above.71,78 WPs are gen-
erated for hydration sites by a combination of thermodynamic analysis, MIFs, and docking-based strategies. However,
in contrast to HSPR, the WP method generates a single 3D pharmacophore in a highly automated fashion with a com-
parably low number of involved features granting high performance in virtual screening campaigns. After optimizing
parameters for the 3D pharmacophore generation procedure against seven pharmaceutically relevant targets, the
authors were able to generate successful 3D pharmacophores for four out of seven targets.
PyRod (2019). Similar to WP and HSRP, the free and open-source software PyRod focuses on water molecules in
protein binding pockets to generate 3D pharmacophores for virtual screening.79 However, instead of determining ther-
modynamic properties of hydration sites, PyRod analyzes the protein environment of water molecules in protein bind-
ing pockets based on fast-to-calculate pharmacophore inspired heuristic scoring functions. This information is further
processed to visualize pharmacophoric binding pocket characteristics in the form of dynamic dMIFs and to generate
pharmacophore features for virtual screening (Figure 5). Since scoring is only performed in the presence of water mole-
cules, pharmacophore features are preferentially placed at hydration sites with high water occupancy. Replacing such
water molecules with a ligand moiety results in a gain of entropy and hence increases the chance for discovery of high
affinity ligands. Similar to other apo-based pharmacophore methods, the unrefined 3D pharmacophore contains too
many features for efficient virtual screening. Hence, the user must first preselect pharmacophore features based on
dMIFs and their arrangement in the binding pocket. The features of this focused 3D pharmacophore are subsequently
combined to generate a pharmacophore library based on user-defined characteristics, for example, maximal and
FIGURE 4 Dynophores (dynamic pharmacophores) unveil dynamic binding mode changes of the sphingosine-1-phosphate receptor
ligand ML056 during a 100 ns MD simulation. The yellow point clouds indicate lipophilic contacts, the red and green features represent
hydrogen bond acceptor or donor, respectively, and a positively charged area is shown as a blue point cloud. The percentages next to the
features refer to their occurrence frequency during the simulation. In the example shown, a major part of the molecule remains in its initial
orientation resulting in nearly sphere-like distributions of the according feature point clouds (right part). The lipophilic tail is much more
flexible within the binding site as indicated by the banana-shaped feature cloud (left part). MD, molecular dynamics
12 of 20 SCHALLER ET AL.
minimal number of independent features or hydrophobic contacts. A Python script is provided allowing for evaluation
of the generated pharmacophore library using LigandScout.11 PyRod pharmacophores performed better than docking
for three out of five pharmaceutically relevant targets, according to ROC analysis in a retrospective evaluation and pro-
vides a directly usable workflow for efficient virtual screening.
AutoDock Bias with Solvent Sites (2019) employs cosolvent based pharmacophores to bias docking algorithms toward
hotspots of probe molecule binding for improving virtual screening performance.80,102,103 First, the authors performed
cosolvent MD simulations of proteins in the presence of water and ethanol. Next, the trajectories were analyzed to iden-
tify hotspots for binding of the ethanol hydroxyl- and methyl-group. Finally, the calculated free energies of ethanol hot-
spots were used to introduce an additional energy term to the docking algorithm of AutoDock 4.28,80 The biased
docking performance was retrospectively evaluated, showing improved performance compared to the standard docking
procedure in the majority of investigated test systems.103
Pharmmaker (2020) analyzes cosolvent simulations to generate 3D Pharmacophores for virtual screening.81 In the
presented case study, cosolvent simulations were performed using six different probe molecules and subsequently
employed to assess the druggability of different binding sites with DruGUI.104 The most druggable binding site was sub-
sequently processed with Pharmmaker by selecting protein residues with high probe-specific affinities and by identify-
ing snapshots that show the most frequent interactions between protein residues and probe molecules. Finally, 3D
pharmacophores were generated from selected snapshots and employed for virtual screening with Pharmit,89 a web
application for pharmacophore screening described later in this review.
In addition to 3D pharmacophore modeling, the benefit of multiple protein conformations in enhancing the performance
of molecular docking is also frequently discussed.105 However, ensemble docking in multiple X-ray structures revealed minor
improvements in screening performance in only some test systems, which hardly justifies the increased computational
costs.106 Clustering protein conformations could be a solution to reduce the computational costs, but fails to identify the most
relevant protein conformations from MD simulations.107 In contrast to molecular docking, the presented 3D pharmacophore
approaches show clear advantages over traditional static pharmacophore modeling. Dynophores, for example, provide a sta-
tistical characterization of interactions in the form of volumetric feature density clouds. Escaping from the spherical nature
of traditional pharmacophore features in conjunction with the representation of pharmacophore features as probability den-
sity functions represents a strong opportunity to boost virtual screening performance. Furthermore, approaches like PyRod
consider entropic contribution of ligand binding which can only be poorly estimated by static methods. In comparison to
these advanced pharmacophore approaches, ensemble docking represents a computationally expensive parallelization of the
same underlying algorithms. Hence, important information contained in MD simulations is not properly considered,
resulting in comparably poor improvement of performance.
4.2 | Training machine learning models with pharmacophoric descriptors
In recent years, machine learning and artificial intelligence have witnessed tremendous amount of attention in the pub-
lic media. The simultaneous improvement in computing power and increase of available data have heavily influenced
FIGURE 5 PyRod applied to the binding pocket of cyclin-dependent kinase 2. (a) The protein environment of water molecules is
analyzed to generate (b) dynamic molecular interaction fields (dMIFs) describing the pharmacophoric characteristics of the binding pocket,
(c) which can be translated into pharmacophore features for virtual screening. Yellow—hydrophobic contact, green—hydrogen bond donor,
red—hydrogen bond acceptor
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the modern drug discovery process.108 Moreover, the concept of 3D pharmacophores was employed to develop several
new machine learning methods.
HS-pharm (2008). The Hot-Spots-Guided Receptor-Based Pharmacophores (HS-Pharm) approach trains machine
learning models to reduce the number of features from apo-based 3D pharmacophore models.30 The binding cavities of
~3,500 resolved protein–ligand complexes were analyzed and over 600 k atoms were distributed into interacting and
noninteracting groups. Atom-based cavity fingerprints were generated from the gathered cavity atoms, collecting data
about pharmacophoric and torsional properties, involved residues, and their protein environment. Decision trees and
Bayesian classifiers were trained and tested on these fingerprints to detect cavity atoms important for ligand binding.
Evaluation of the approach identified random forest decision trees to perform best according to enrichment and ROC
analysis. Finally, this approach was applied to three pharmaceutical relevant drug targets resulting in the generation of
3D pharmacophores performing better than docking in two out of three cases.
Pharm-IF (2010). The pharmacophore-based interaction fingerprint Pharm-IF was evaluated as input for several
machine learning algorithms to rank docking poses of small molecules.82 Interaction fingerprints encoding the type
and distance of interaction partners were generated for all available atomistic models of five pharmaceutically relevant
drug targets. These were subsequently used to train several machine learning algorithms to rank docking poses of
known actives and decoys. In a retrospective evaluation, Pharm-IF fingerprints in combination with support-vector
machines showed the best enrichment, outperforming other machine learning algorithms and a docking scoring func-
tion. Employing Pharm-IF to train machine learning algorithms resulted in better enrichment compared to employing
PLIF, a protein–ligand interaction fingerprint implemented in MOE.13 In contrast to Pharm-IF, this fingerprint does
not encode the distance, which suggests an important contribution of the distance to successful predictions. Interest-
ingly, learning on more than five crystal structures enabled models to predict activity better than docking scores for all
studied targets.
DeepSite and related softwares (2017). The DeepSite software employs convolutional neural networks typically used
for analyzing visual imagery to predict the druggability of protein binding pockets.83 Atomic-based pharmacophoric
descriptors were assigned to grid points covering the protein of approximately 7,000 protein–ligand complexes. These
grids were subsequently divided into subgrids, which were labeled as a binding site if their geometric center was within
4 Å of the binding site's geometric center. These 3D images of the binding pocket represented by 3D grids of
pharmacophoric descriptors were used to train a convolutional neural network. The DeepSite cavity detection was
found to perform better than other state-of-the-art detection algorithms. Similar approaches that also use
pharmacophoric descriptors to train convolutional neural networks were later used to predict binding affinities of small
molecules (KDEEP
84) and to guide the design of novel molecules (LigVoxel,85 LigDream86). All of the aforementioned
approaches are implemented in software packages for local installation but can also be used free of charge as web
applications.
4.3 | Web applications employing 3D pharmacophores
Although web applications do not necessarily represent an advancement of the 3D pharmacophore concept itself, they
do advance their usability, bringing 3D pharmacophores into the internet age. Since a local installation of software is
not needed and all web applications presented are freely available for academic research, users can circumvent license
fees and screen databases with millions of molecules without the need for high-performance computational resources.
Thus, 3D pharmacophore searches become available to a larger number of users.
PharmaGist (2008). The PharmaGist web application allows for ligand-based 3D pharmacophore generation.87 Each
submitted ligand is analyzed for rotatable bonds important for flexible molecule alignment and for pharmacophoric fea-
tures used for alignment to a reference ligand. A user-specified maximal number of 3D pharmacophores is generated,
and the output comprising 3D pharmacophores and aligned molecules can be downloaded.
PharmMapper (2010). The PharmMapper web application can be used for target fishing of small molecules impor-
tant for off-target prediction and polypharmacology studies.88 More than 53,000 3D pharmacophore models were gener-
ated from approximately 23,000 protein database (PDB) crystal structures based on protein–ligand interactions or
involving a cavity detection algorithm to identify potential allosteric binding sites. Submitted molecules are scored by
their match to all deposited 3D pharmacophore models.
Pharmer-based web applications (2012). The Pharmer virtual screening software10 was employed for several web
applications enabling the efficient virtual screening of several small molecule databases. AnchorQuery is specialized for
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the identification of protein–protein interaction inhibitors.90 The user uploads a protein–protein complex and specifies
an anchor residue that is likely to be important for protein–protein interaction. This anchor residue will become part of
a 3D pharmacophore that is used to screen a multimillion compound library of synthesizable small molecules.
ZINCPharmer can be used to perform a virtual screening of the ZINC database, a free virtual library collecting commer-
cially available compounds from different vendors.91,109 The web application supports the import of 3D
pharmacophores but can also be used to generate 3D pharmacophore models from scratch. Lastly, Pharmit enables the
virtual screening of several commercial vendors as well as other noncommercial databases including ChEMBL and
PubChem.89,110,111 The 3D pharmacophores can be either designed from a protein–ligand complex or, a ligand. The
import of 3D pharmacophore models in several data formats is also supported.
5 | CONCLUSION
In this review, we have given an overview of the principles of 3D pharmacophores and their role in drug discovery. The
fact that 3D pharmacophore models are universal, editable, and comprehensive allows them to be applied in different
scenarios.
A major application field is the identification of novel ligands through virtual screening. For this purpose, 3D
pharmacophore models are the sole technique that can be applied in either a ligand-based or a structure-based manner.
In both ways, 3D pharmacophore models are computationally very efficient, enabling the virtual screening of very large
databases. The basic concept of abstracting chemical functionality allows for scaffold hopping and enriches the chemi-
cal diversity of hit lists. Altogether, this grants researchers more flexibility regarding available data, computational
resources, and testing capabilities. The case studies that we selected highlight the power of pharmacophore-based vir-
tual screening for drug discovery and show their applicability to challenging targets. Also, increasingly popular
fragment-based drug discovery campaigns can benefit from pharmacophore screening by a dramatic reduction of frag-
ments tested in vitro and by rationalizing fragment growing with constant fragment core interactions.54,55
Besides virtual screening, 3D pharmacophores are well suited to study and visualize binding modes of drug-like
molecules. Their composition of a limited number of chemically defined interaction features make them understand-
able and intuitive. This represents a major advantage in interdisciplinary projects, since 3D pharmacophore models are
able to rationalize various pharmacological effects. For this objective, 3D pharmacophores are typically combined with
other methods such as docking, MD simulations, or machine learning. The selected case studies for this field underline
the power of 3D pharmacophores to mechanistically explain and understand protein functionality. Additionally, 3D
pharmacophores are an excellent tool for communication between researchers, a factor that is often underestimated.
However, besides the aforementioned advantages and possibilities, classic 3D pharmacophore models also have cer-
tain drawbacks. They represent static models for highly dynamic systems and their interaction features are restricted to
simple geometries (e.g., spherical features). Moreover, they share a shortcoming with other modeling techniques, which
all are focused on estimating the enthalpy of molecular interactions but are suboptimal for the description of entropic
effects. However, enthalpy and entropy both contribute to the change in free energy of ligand binding to a macromole-
cule. Although the basic concept of 3D pharmacophore generation and its application to virtual screening has not chan-
ged in the last 30 years, there are various developments in the field that aim at addressing these shortcomings.
The combination of 3D pharmacophore models with MDs is therefore a consequent evolution with great potential.
Different approaches to integrating MDs into 3D pharmacophore modeling have been reported and described in this
review.71–75,77–79,81,103 However, only the dynophore method represents a fully automated approach, which tackles two
drawbacks of classical 3D pharmacophores at a time.74 The dynophore application reveals a new perspective on ligand
binding by providing visualization of pharmacophoric features that escape from the traditional spherical geometry and
by delivering statistics that report feature occurrence frequencies and different binding modes over the course of a tra-
jectory. The direct usage of these property-density functions for virtual screening would represent a true paradigm shift
in 3D pharmacophore modeling.
Several advanced approaches also consider entropic effects of ligand binding for 3D pharmacophore
modeling.71–73,78,79,81,103 PyRod, for instance, analyzes the protein environment of water molecules in MD simulations,
which allows for placement of pharmacophore features at hydration sites with certain thermodynamic characteristics.79
Such hydration sites may harbor water molecules in a highly hydrophobic protein environment or heavily restrain
water molecules via hydrogen bonds and the shape of the binding pocket. The restriction of 3D pharmacophores to
entropically and enthalpically important sites render such approaches valuable tools for virtual screening campaigns,
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especially for those generating 3D pharmacophores from an apo structure. Importantly, PyRod is a free and open-access
tool making such strategies accessible to a broader user base.
The combination of 3D pharmacophore concept and machine learning/artificial intelligence is only in its beginning
stages. Although some approaches already exist,30,82–86 we predict an increasing number of studies and methods that
aim to use pharmacophore features as descriptors or try to generate 3D pharmacophores from big data. Another trend
that we observe is the availability of freely available web services for pharmacophore-based virtual screening.87–91
The recent developments in the field of 3D pharmacophores are promising and afford the opportunity to employ 3D
pharmacophores in ever-increasing ways and more challenging situations, such as multitarget prediction, modeling
binding kinetics, or pathway-specific receptor activation. Overall, 3D pharmacophores represent an essential part of the
toolbox for computer-aided drug design and are perfectly apt to identify novel ligands and understand their interaction
with the macromolecular target.
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